<DOC>
	<DOCNO>NCT01476163</DOCNO>
	<brief_summary>This program allow physicians request permission Amicus Therapeutics ( Amicus ) treatment access migalastat hydrochloride ( HCl ) specific adult patient Fabry disease . Treatment open label 6 month renewal every 6 month .</brief_summary>
	<brief_title>Physician Initiated Expanded Access Request Migalastat Individual Patients With Fabry Disease</brief_title>
	<detailed_description>This Physician Initiated Request program allows physicians request permission Amicus receive migalastat HCl specific patient Fabry disease mutation amenable treatment , access available treatment alternative , meet requirement participation exist migalastat clinical study . Up 20 patient worldwide may treat . Patients must meet specific criterion receive Amicus permission participation . Key criteria participation include : 16-74 year old ; Confirmed GLA gene mutation show responsive migalastat ; Have treatment option either unsuitable enzyme replacement therapy ( ERT ) unable access ERT . Requirements sufficient kidney function . If permission grant , initial approval 6 month supply migalastat HCl renewal every 6 month available upon meet continued eligibility .</detailed_description>
	<mesh_term>Fabry Disease</mesh_term>
	<criteria>Confirmed GLA mutation predict responsive migalastat human embryonic kidney ( HEK293 ) cellbased assay 1674 year age Strong clinical indication treatment Fabry disease No treatment option include either unsuitable ERT unable access ERT Appropriate female male contraception Willing receive treatment migalastat HCl via program include sign authorization share clinical data Estimated glomerular filtration rate ( eGFR ) GFR &lt; 30 mL/minute Scheduled renal organ transplant replacement therapy Receiving GLYSET® ( miglitol ) , ZAVESCA® ( miglustat ) enzyme replacement therapy FABRAZYME® ( agalsidase beta ) REPLAGAL™ ( agalsidase alpha ) Contraindication migalastat , i.e. , sensitivity iminosugar miglustat , miglitol Treated another investigational drug within 30 day start migalastat HCl treatment Unable comply study requirement deem otherwise unsuitable study entry opinion investigator .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>AT1001</keyword>
	<keyword>Lysosomal storage disease</keyword>
	<keyword>Lysosomal Storage Disorder</keyword>
	<keyword>migalastat</keyword>
	<keyword>Fabry disease</keyword>
	<keyword>Fabry</keyword>
	<keyword>Amicus</keyword>
</DOC>